Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.

Advances in therapy - 1 Jul 2022

Paik Paul K, Pfeiffer Boris M, Vioix Helene, Garcia Andrea, Postma Maarten J

Abstract excerpt

INTRODUCTION: MET exon 14 skipping in patients with advanced non-small cell lung cancer (aNSCLC), can be targeted with MET inhibitors including tepotinib, capmatinib, savolitinib, and crizotinib. Matching-adjusted indirect comparison (MAIC) methodology was used to compare outcomes data between agents and to address bias from differences in baseline characteristics. METHODS: Patient-level data from the VISION...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mycobacterium avium Complex

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Pyridazines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35543963
DOI: 10.1007/s12325-022-02163-9
PMCID: PMC9239936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.PMID 35543963Read ↗

Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.Semantic proximity Read ↗

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.Semantic proximity Read ↗

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.Semantic proximity Read ↗

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.Semantic proximity Read ↗

Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.Semantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.